Rapid Resolution of Suicidal Ideation After a Single Infusion of an N -Methyl- D -Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Objective Suicidal ideation is a medical emergency, especially when severe. Little research has been done on pharmacologic interventions that could address this problem. Ketamine, an N-methyl-D-asparate antagonist, has been reported to have antidepressant effects within hours. We examined the effects of a single dose of ketamine on suicidal ideation in subjects with treatment-resistant major depressive disorder (MDD). Method Thirty-three subjects with DSM-IV-diagnosed MDD received a single open-label infusion of ketamine (0.5 mg/kg) and were rated at baseline and at 40, 80, 120, and 230 minutes postinfusion with the Scale for Suicide Ideation (SSI), the Montgomery-Åsberg Depression Rating Scale, the Hamilton Depression Rating Scale, and the Beck Depression Inventory. The study was conducted between October 2006 and January 2009. Results Suicidal ideation scores decreased significantly on the SSI as well as on the suicide subscales of other rating instruments within 40 minutes; these decreases remained significant through the first 4 hours postinfusion (P Conclusions Suicidal ideation in the context of MDD improved within 40 minutes of a ketamine infusion and remained improved for up to 4 hours postinfusion. Future studies with ketamine in suicidal ideation are warranted due to the potential impact on public health. Trial registration clinicaltrials.gov Identifier: NCT00088699.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The rapid-acting dissociative agent ketamine, which has shown its efficacy in treating depression, is known to increase BDNF levels (37, 38).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [38]
In the citing paper
“Extensive experience with human patients has established that ketamine exerts rapid, robust antidepressant, antianhedonic, and antisuicidal actions within two hours of administration that are sustained for at least seven days in patients with major depression following a single infusion or intranasal administration [129-133].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [131]
In the citing paper
“Recent studies report that ketamine also reduces suicide ideation, a major advance over typical antidepressants with low efficacy and delayed onset of action151,152.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [151]
In the citing paper
“Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions in treatment-resistant patients.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [7]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationAssessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
Linehan, M. M., Comtois, K. A., Murray, A. M., Brown, M. Z., Gallop, R. J., Heard, H. L., Korslund, K. E., Tutek, D. A., Reynolds, S. K., & Lindenboim, N. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.757 · Cited by 2,025
Assessment of Depression: The Depression Inventory
Beck, A. T., & Beamesderfer, A. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000395074 · Cited by 1,832
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Cognitive Therapy for the Prevention of Suicide Attempts: A Randomized Controlled Trial
Brown, G. K., Ten Have, T., Henriques, G. R., Xie, S. X., Hollander, J. E., & Beck, A. T. (2005) · JAMA · doi:10.1001/jama.294.5.563 · Cited by 1,045
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Cited by
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Self-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
“, 2012), even exhibiting efficacy in treatment-resistant populations (DiazGranados et al., 2010; Murrough et al., 2013; Zarate et al., 2006).”
BackgroundMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
BDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Self-citationLeonard, B., & Maes, M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.12.005 · Cited by 805
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
“ketamine may exert a unique anti-SI effect even in the absence of a full response and is consistent with previous reports highlighting the potential anti-SI effects of ketamine in depressed populations (10, 24, 25).”
Duman, R. S., & Voleti, B. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.004 · Cited by 714
Ketamine Pharmacology: An Update ( Pharmacodynamics and Molecular Aspects, Recent Findings )
Mion, G., & Villevieille, T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12099 · Cited by 711
“Studies clearly showed ketamine antidepressive properties [64–66], with a rapid resolution of suicidal ideation, even during bipolar disorder [64,67].”
BackgroundWilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Self-citationCanuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580
Zhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538
Signaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537
“Both the PFC and hippocampus and related circuitry have been implicated in depression and antidepressant response (Drevets and Furey, 2010; Macqueen et al., 2008), and in the actions of ketamine (Li et al., 2010; Autry et al., 2011).”
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Self-citationA Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480
“However, previous studies of patients with unipolar TRD did not describe effects of IV ketamine on anxiety, with the exception of an early randomized controlled trial (11) and an open-label study (33) reporting significant improvement in”
ResultSingh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17060647 · Cited by 431
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421
“Moreover, suicidal ideation in the context of TRD has also been reported to be significantly reduced with ketamine infusion (Diazgranados et al., 2010).”
BackgroundKetamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418
“This has since been replicated in two open-label investigations of MDD patients and in one RCT of BD patients (15,24,44).”
BackgroundResultSelf-citationRapid-acting glutamatergic antidepressants: the path to ketamine and beyond
Krystal, J. H., Sanacora, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.026 · Cited by 406
“symptoms of depression improve, including suicidal ideation (38,39).”
BackgroundLiu, R.-J., Lee, F. S., Li, X.-Y., Bambico, F., Duman, R. S., & Aghajanian, G. K. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.030 · Cited by 403
“Moreover, a single dose of ketamine is effective in rapidly resolving suicidal ideation in emergency room situations (56-57).”
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
“These effects persist for 3–18 days, long after the drug has cleared the patient’s system (Berman et al , 2000; Diazgranados et al , 2010a,b; Murrough et al , 2012; Valentine et al , 2011; Zarate et al , 2006, 2012a).”
Ketamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385
Duman, R. S., & Li, N. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0357 · Cited by 362
Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016) · Psychological Medicine · doi:10.1017/s0033291716000064 · Cited by 359
“Furthermore, ketamine reduced suicidal thoughts in both open (Price et al. 2009; Diazgranados et al. 2010b; Larkin & Beautrais, 2011) and controlled (Zarate et al.”
BackgroundMethodResultSelf-citationKoike, H., Iijima, M., & Chaki, S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.035 · Cited by 346
Connecting inflammation with glutamate agonism in suicidality
Erhardt, S., Lim, C. K., Linderholm, K. R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T. T., Träskman-Bendz, L., Guillemin, G. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.248 · Cited by 345
“Interestingly, the NMDA-receptor antagonist ketamine was recently shown to reduce suicidality in four small-scale clinical studies (DiazGranados et al, 2010b; Larkin and Beautrais, 2011; Price et al, 2009; Zarate et al, 2012).”
BackgroundPrice, R. B., Iosifescu, D. V., Murrough, J. W., Chang, L. C., Al Jurdi, R. K., Iqbal, S. Z., Soleimani, L., Charney, D. S., Foulkes, A. L., & Mathew, S. J. (2014) · Depression and Anxiety · doi:10.1002/da.22253 · Cited by 345
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309
Self-citationBay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304
“Interestingly, new evidence has shown that ketamine has an effect in treatment-resistant depression and suicidality (Machado-Vieira et al., 2009; DiazGranados et al., 2010; Zarate et al., 2006).”
BackgroundKetamine for rapid reduction of suicidal ideation: a randomized controlled trial
Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., Lener, M., Kautz, M., Kim, J., Stern, J. B., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715001506 · Cited by 297
“…of ketamine studies in mood disorders provide initial support for the antisuicidal ideation (SI) effects of ketamine (Price et al. 2009, 2014; DiazGranados et al. 2010a, b; Ballard et al. 2014) and a single open-label proof of concept study of ketamine conducted in an emergency department…”
BackgroundResultSuicide risk assessment and intervention in people with mental illness
Bolton, J. M., Gunnell, D., & Turecki, G. (2015) · BMJ · doi:10.1136/bmj.h4978 · Cited by 294
Ballard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286
“Ketamine is a glutamatergic, N-methyl-D-aspartate (NMDA) receptor antagonist that has rapid-acting antidepressant effects (Berman et al., 2000; Diazgranados et al., 2010b; Ibrahim et al., 2012; Zarate et al., 2006) in both unipolar and bipolar depressed patients.”
BackgroundMethodResultInfluentialSelf-citationBurgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284
“…effects with onset within 2 h and duration of effect up to several weeks, following a single dose in patients with treatment-resistant depression and bipolar depression (aan het Rot et al, 2010; Berman et al, 2000; Diazgranados et al, 2010a, b; Price et al, 2009; Zarate et al, 2006a).”
BackgroundInfluentialThe use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279
De Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 259
“…of subanesthetic doses of ketamine (0.5mg/kg, infused over 40min) for depression and suicidal ideation in MDD patients resistant to selective serotonin reuptake inhibitors (Berman et al., 2000; Zarate et al., 2006a; Price et al., 2009, 2014; DiazGranados et al., 2010; Ballard et al., 2014).”
Majić, T., Schmidt, T. T., & Gallinat, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568040 · Cited by 261
“Strong but short-lasting effects have been found for treatment-resistant unipolar depression (Zarate et al., 2006) and bipolar depression (DiazGranados et al., 2010a) as well as suicidal ideation (DiazGranados et al., 2010b).”
Backgroundde Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269
“The rapid-acting dissociative agent ketamine, which has shown its efficacy in treating depression, is known to increase BDNF levels (37, 38).”
BackgroundMacedo, D., Filho, A. J. M. C., Soares de Sousa, C. N., Quevedo, J., Barichello, T., Júnior, H. V. N., & Freitas de Lucena, D. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.09.012 · Cited by 261
The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments
Machado-Vieira, R., Baumann, J., Wheeler-Castillo, C., Latov, D., Henter, I. D., Salvadore, G., & Zarate, C. A. (2010) · Pharmaceuticals · doi:10.3390/ph3010019 · Cited by 263
“Interestingly, ketamine also significantly reduced suicidal ideation in individuals with treatmentresistant MDD [114,115].”
BackgroundSelf-citationKetamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“However, none of these studies predicted the distinctively rapid and robust antidepressant effects of a single ketamine dose in depressed patients observed in the initial pilot study, nor the ef fi cacy in treatment-resistant symptoms of depression, bipolar disorder [30] or suicide ideation [31].”
ResultRole of Inflammation in Suicide: From Mechanisms to Treatment
Brundin, L., Bryleva, E. Y., & Thirtamara Rajamani, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.116 · Cited by 257
Yang, C., Ren, Q., Qu, Y., Zhang, J.-C., Ma, M., Dong, C., & Hashimoto, K. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.016 · Cited by 250
Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
“In addition to its rapid antidepressant effects, (R,S)-ketamine rapidly reduces suicidal ideation in depressed patients (DiazGranados et al., 2010).”
BackgroundSex differences in the antidepressant-like effects of ketamine
Carrier, N., & Kabbaj, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.12.009 · Cited by 251
“In this population, a single injection of small dose of ketamine induced a rapid resolution of suicidal ideation (DiazGranados et al., 2010; Price et al., 2009).”
BackgroundKetamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects
Nugent, A. C., Ballard, E. D., Gould, T. D., Park, L. T., Moaddel, R., Brutsche, N. E., & Zarate, C. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0028-2 · Cited by 250
Self-citationKetamine for Treatment-Resistant Unipolar Depression: Current Evidence
Mathew, S. J., Shah, A., Lapidus, K., Clark, C., Jarun, N., Ostermeyer, B., & Murrough, J. W. (2012) · CNS Drugs · doi:10.2165/11599770-000000000-00000 · Cited by 238
“The acute, rapid-onset, anti-suicidal properties of open-label IV ketamine (0.5mg/kg over 40 minutes) were recently confirmed in a report by the NIMH group in a sample of 33 patients with TRD.[97] In this study suicidal ideation scores decreased on the SSI within 40 minutes of infusion, and remained low throughout the…”
BackgroundInfluentialThe role of ketamine in treatment-resistant depression: A systematic review
Serafini, G., Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140619204251 · Cited by 234
The Addictive Model of Self-Harming (Non-suicidal and Suicidal) Behavior
Blasco-Fontecilla, H., Fernández-Fernández, R., Colino, L., Fajardo, L., Perteguer-Barrio, R., & de Leon, J. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00008 · Cited by 203
“Furthermore, there is increasing evidence that a single infusion of ketamine, an N-methyl-d-asparate antagonist, traditionally used as anesthetic, but also with analgesic properties, can lead to a rapid resolution of suicidal ideation in patients with treatment-resistant major depressive disorder (76).”
BackgroundBidirectional relationship between sleep and depression
Yasugaki, S., Okamura, H., Kaneko, A., & Hayashi, Y. (2025) · Neuroscience Research · doi:10.1016/j.neures.2023.04.006 · Cited by 200
Ketamine and depression: a narrative review
Corriger, A., & Pickering, G. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s221437 · Cited by 211
Glutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228
Self-citationPharmacological approaches to the challenge of treatment-resistant depression
Ionescu, D. F., Rosenbaum, J. F., & Alpert, J. E. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/dionescu · Cited by 212
Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., Lapidus, K., McGirr, A., Somogyi, A. A., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv124 · Cited by 226
Yang, C., Qu, Y., Fujita, Y., Ren, Q., Ma, M., Dong, C., & Hashimoto, K. (2017) · Translational Psychiatry · doi:10.1038/s41398-017-0031-4 · Cited by 223
Brain NMDA Receptors in Schizophrenia and Depression
Adell, A. (2020) · Biomolecules · doi:10.3390/biom10060947 · Cited by 212
Serial infusions of low-dose ketamine for major depression
Rasmussen, K. G., Lineberry, T. W., Galardy, C. W., Kung, S., Lapid, M. I., Palmer, B. A., Ritter, M. J., Schak, K. M., Sola, C. L., Hanson, A. J., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113478283 · Cited by 217
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
“In another study of 33 subjects with treatment-resistantMDDwho received a single ketamine infusion, suicidal ideation scores decreased significantly within 40 minutes, an effect that remained significant for 4 hours postinfusion.([123]) One study conducted in a naturalistic setting (e.”
BackgroundSelf-citationThe role of cytokines in the pathophysiology of suicidal behavior
Ganança, L., Oquendo, M. A., Tyrka, A. R., Cisneros-Trujillo, S., Mann, J. J., & Sublette, M. E. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.10.008 · Cited by 217
“Moreover, quinolinic acid is an N-methyl-D-aspartate (NMDA) receptor agonist; and ketamine, a known NMDA receptor antagonist, reduced suicidality in some recent studies (DiazGranados et al., 2010; Larkin and Beautrais, 2011).”
BackgroundMatveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Carreno, F. R., Donegan, J. J., Boley, A. M., Shah, A., DeGuzman, M., Frazer, A., & Lodge, D. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.176 · Cited by 205
Witt, K., Potts, J., Hubers, A., Grunebaum, M. F., Murrough, J. W., Loo, C., Cipriani, A., & Hawton, K. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419883341 · Cited by 202
“…et al., 2019; Phillips et al., 2017; Popova et al., 2018; Rodriguez et al., 2013; Yoosefi et al., 2014; Zhong et al., 2016) or because they were secondary publications of studies we had already included in the review (e.g. DiazGranados et al., 2010; Lally et al., 2014; Zarate et al., 2006).”
BackgroundIadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201
Self-citationClinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“Diazgranados et al., 2010b Ketamine (.5 mg/kg, i.v.)/randomized double-blind placebo-controlled 18 (12)/treatmentresistant BPD, current depressive episode Significant decrease in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from 40 minutes to 3 days post-ketamine infusion (p % .001);…”
Brundin, L., Sellgren, C. M., Lim, C. K., Grit, J., Pålsson, E., Landén, M., Samuelsson, M., Lundgren, K., Brundin, P., Fuchs, D., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.133 · Cited by 195
Naughton, M., Clarke, G., O′Leary, O. F., Cryan, J. F., & Dinan, T. G. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.11.014 · Cited by 190
“DiazGranados et al. (2010b) gave 33 subjects with treatment-resistant MDD a single open-label infusion of ketamine (0.5 mg/kg).”
BackgroundResultInfluentialCircadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder
Bunney, B. G., Li, J. Z., Walsh, D. M., Stein, R., Vawter, M. P., Cartagena, P., Barchas, J. D., Schatzberg, A. F., Myers, R. M., Watson, S. J., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.138 · Cited by 180
(2013) · PubMed · Cited by 192
Alnefeesi, Y., Chen-Li, D., Krane, E., Jawad, M. Y., Rodrigues, N. B., Ceban, F., Di Vincenzo, J. D., Meshkat, S., Ho, R. C. M., Gill, H., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.04.037 · Cited by 186
Ionescu, D. F., Bentley, K. H., Eikermann, M., Taylor, N., Akeju, O., Swee, M. B., Pavone, K. J., Petrie, S. R., Dording, C., Mischoulon, D., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.037 · Cited by 179
The role of inflammation in suicidal behaviour
Brundin, L., Erhardt, S., Bryleva, E. Y., Achtyes, E. D., & Postolache, T. T. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12458 · Cited by 172
“Noteworthy, the findings of exceptionally high levels of the NMDA receptor agonist QUIN in the CNS of suicidal patients could provide a neurobiological rationale for the rapid remedial effects of ketamine, an NMDA receptor antagonist, on suicidal ideation (78, 79).”
BackgroundYang, C., Hu, Y.-M., Zhou, Z.-Q., Zhang, G.-F., & Yang, J.-J. (2013) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.724118 · Cited by 173
“ketamine has an ability to ameliorate the symptoms of depressed patients, especially in patients with treatment-resistant depression (20,21).”
BackgroundKetamine as a Novel Antidepressant: From Synapse to Behavior
Murrough, J. W. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.244 · Cited by 172
Effects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00134 · Cited by 171
Convergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
Self-citationmTOR activation is required for the antidepressant effects of mGluR2/3 blockade
Dwyer, J. M., Lepack, A. E., & Duman, R. S. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001702 · Cited by 169
“While ketamine produces robust antidepressant effects, the deleterious side effects and abuse potential limit its widespread use for treatment of depression, as well as suicide (DiazGranados et al., 2010; Larkin and Beautrais, 2011).”
BackgroundKynurenine pathway metabolites and suicidality
Bryleva, E. Y., & Brundin, L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.034 · Cited by 168
“The effect of ketamine on suicidal ideation has proven to occur as early as 40 min after the start of infusion and to be long lasting, up to 10 days after infusion (DiazGranados et al., 2010; Ibrahim et al., 2012; Larkin and Beautrais, 2011; Zarate et al., 2012).”
Irwin, S. A., Iglewicz, A., Nelesen, R. A., Lo, J. Y., Carr, C. H., Romero, S. D., & Lloyd, L. S. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0617 · Cited by 167
Niciu, M. J., Henter, I. D., Luckenbaugh, D. A., Zarate, C. A., & Charney, D. S. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135950 · Cited by 161
“In the study by Li and colleagues (55), Ro(25)-6981 increased the expression of postsynaptic and second messenger/signal transduction cascade intermediaries (including mTOR) on a similar time course to that identified above.”
BackgroundSelf-citationGlutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
Self-citationClinically Significant Drug Interactions with Newer Antidepressants
Spina, E., Trifirò, G., & Caraci, F. (2012) · CNS Drugs · doi:10.2165/11594710-000000000-00000 · Cited by 160
Ketamine for the treatment of addiction: evidence and potential mechanisms
Ivan Ezquerra-Romano, I., Lawn, W., Krupitsky, E., & Morgan, C. J. A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.017 · Cited by 163
“This was a breakthrough in psychiatry and more research replicated these results in the following years (DiazGranados et al., 2010; Sos et al., 2013; Singh et al., 2016; Zarate et al., 2006).”
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder
Niciu, M. J., Ionescu, D. F., Richards, E. M., & Zarate, C. A. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-013-1130-x · Cited by 155
Self-citationSanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
“On the basis of reports of ketamine’s rapid effects on suicidal ideation (DiazGranados et al, 2010; Price et al, 2014), several controlled studies are currently underway examining the short-term clinical benefits of ketamine in crisis settings such as in the emergency department with suicidal…”
BackgroundLumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816071116 · Cited by 158
Self-citationRemodeling of axo-spinous synapses in the pathophysiology and treatment of depression
Licznerski, P., & Duman, R. S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.057 · Cited by 157
“Ketamine is also effective for the treatment of suicide ideation (DiazGranados et al., 2010b) and BD depression (Diazgranados et al., 2010a).”
Li, Y.-F. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107494 · Cited by 170
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149
“In addition, rapid antisuicidal effects have been reported with ketamine [2 ,5,6,7].”
BackgroundSelf-citationNeuroinflammation in suicide: Toward a comprehensive model
Courtet, P., Giner, L., Seneque, M., Guillaume, S., Olie, E., & Ducasse, D. (2016) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1054879 · Cited by 146
“…a single ketamine infusion quickly improved SI (as early as 40 min post-administration) (Berman et al. 2000; Kudoh et al. 2002; Price et al. 2009; DiazGranados et al. 2010; Larkin and Beautrais 2011; Thakurta et al. 2012; Zarate et al. 2012; Adults who experienced childhood trauma exhibit HPA…”
BackgroundMartinotti, G., Vita, A., Fagiolini, A., Maina, G., Bertolino, A., Dell'Osso, B., Siracusano, A., Clerici, M., Bellomo, A., Sani, G., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.043 · Cited by 146
Caddy, C., Giaroli, G., White, T. P., Shergill, S. S., & Tracy, D. K. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313507739 · Cited by 138
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
Self-citationPhillips, J. L., Norris, S., Talbot, J., Hatchard, T., Ortiz, A., Birmingham, M., Owoeye, O., Batten, L. A., & Blier, P. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0570-x · Cited by 139
Chandley, M. J., Szebeni, A., Szebeni, K., Crawford, J. D., Stockmeier, C. A., Turecki, G., Kostrzewa, R. M., & Ordway, G. A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000662 · Cited by 111
Zhao, X., Venkata, S. L. V., Moaddel, R., Luckenbaugh, D. A., Brutsche, N. E., Ibrahim, L., Zarate Jr, C. A., Mager, D. E., & Wainer, I. W. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04198.x · Cited by 137
Self-citation
Metadata
- Authors
- DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A.
- Affiliations
- National Institute of Mental Health (US)
- National Institutes of Health (US)
- Corresponding author
- Zarate, Carlos A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-07-13
- Volume
- 71
- Issue
- 12
- Pages
- 1605-1611
- ISSN
- 0160-6689 (ISSN-L)
- PMC
- PMC3012738
- OpenAlex
- W2103255996
- Cited by
- 564
- References
- 41
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 22 · 2023: 21 · 2022: 41 · 2021: 41 · 2020: 39 · 2019: 35 · 2018: 49 · 2017: 33 · 2016: 51 · 2015: 59 · 2014: 52 · 2013: 40 · 2012: 30
- FWCI
- 23.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 MH999999)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- suicidal ideation, ketamine, NMDA receptor antagonists, rapid antidepressant effects, single-dose infusion, hopelessness, anxiety, depression
- MeSH terms
- Adult, Antidepressive Agents, Depression, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Time Factors, N-Methylaspartate, Treatment Outcome, Excitatory Amino Acid Antagonists, Diagnostic and Statistical Manual of Mental Disorders, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.